Company intelligence / Profile preview

Shanghai Yihua Biological Medicine

Shanghai, Shanghai Shi, Chinasccl.org.cn ↗

Ownership: Private
Development stage: Preclinical

Overview

Shanghai Yihua Biological Medicine has advanced its lead asset, Anyu Peibo Capsule, for the treatment of major depressive disorder into Phase 3 clinical development, with randomized, double-blind, placebo-controlled multicenter studies registered and conducted in collaboration with academic centers.

Therapeutic areas: Psychiatry
Modalities: unknown
Industry: Biotech

Drug pipeline

1 asset

anyu peibo

Partnerships

Shanghai Mental Health Center

Beyond the preview

Go deeper on Shanghai Yihua Biological Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Yihua Biological Medicine.

Explore the full profile